Cell Lipo

Cell-Lipo is developing a patented clinic-based device that converts fat into high-viability autologous SVF (adipose-derived stem cells) in ~40 minutes. By combining mechanical processing with advanced energy-assisted methods, it delivers reproducible yields with >90% cell viability, addressing the cost/complexity of enzymatic systems and the inconsistency of mechanical kits. Initial targets include orthopedics (joint-pain injections) and aesthetics (durable fat grafting), with an FDA roadmap that starts with a 510(k) pathway, followed by a longer-term therapeutic claim. Cell-Lipo is raising a $10M Series A to complete development, manufacturing, and regulatory milestones.